



# The Next Generation of Biopsy Devices

**Brevera<sup>®</sup> Breast Biopsy System elevates the standards of stereotactic breast biopsy procedures**

While in her previous role with Mills-Peninsula Women's Center, Harriet Borofsky, MD, acquired Brevera<sup>®</sup> breast cancer biopsy system and found it benefited the patient and physician experience. Now, in her current role at Riverview and Bayshore Medical Centers at Hackensack Meridian Health in New Jersey, she is working to bring Brevera system to her new facility to help elevate the standard of care and differentiate her facility.



**Harriet Borofsky, MD**  
Hackensack Meridian Health  
New Jersey

For more information, contact your Hologic representative

[BreveraBiopsy.com](http://BreveraBiopsy.com)

## Streamlined Procedures and Results

Brevera<sup>®</sup> breast biopsy system with CorLumina<sup>®</sup> imaging technology uniquely combines tissue acquisition, real-time imaging, verification, and advanced tissue handling for an optimal patient and physician experience.

"This technology is a game changer for patients and for the workflow of the center," said Dr. Borofsky. "It helped transform the biopsy program at Mills-Peninsula Women's Center. I miss it every day, and the Brevera system is part of my vision for growing the program at Hackensack Meridian Health."

**"This technology is a game changer for patient and for the workflow of the center."**

Traditional stereotactic procedures require eight steps for a complete biopsy, and sometimes as many as 12 samples. However, Brevera biopsy system allows physicians and technologists to gather samples in three steps by combining tissue acquisition, imaging, verification, and sample prep.<sup>1</sup>

"For me, as a physician, getting real-time feedback on samples and not having to leave the room with the patient's breast in compression is a huge improvement," said Dr. Borofsky. "Having the imaging technology housed in the console is brilliant and makes the process so much easier."

This simplified system means that patients spend less time under compression and

potentially have a more positive breast biopsy experience.

## Advanced Real-Time Imaging

Minutes can matter when it comes to a cancer diagnosis. With real-time imaging of samples, Dr. Borofsky noted that, in her experience, she can start to review the imaging and lesion specimen after only a few samples, reducing not only the time per biopsy procedure but also the chances of complications.

"By the second sample the imaging was coming up for us to examine," said Dr. Borofsky. "Many times, I've had patients say 'Oh, that's it?' because they were so anxious about the procedure. For me, that's a good day."

Brevera system completely reimagines what a breast biopsy procedure should look like, while also allowing access to challenging lesions and supporting a wider spectrum of patients. Thanks to CorLumina imaging technology, physicians can make an informed decision quickly and efficiently without leaving the patient's side.

The built-in image enhancement tools allow physicians and technologists to quickly identify faint calcifications on a high-resolution touchscreen monitor. These fast, efficient procedures can improve workflow, which could potentially help reduce anxiety for patients.

**Brevera<sup>®</sup>**  
Breast Biopsy System

“With Brevera system, you have the technology in the room to make the procedure go as quickly and safely as possible,” said Dr. Borofsky. “Each time you take a sample, you risk complications. So, by taking fewer samples, you decrease the complication rate.”

### Automated Sampling Analysis

Through use of Brevera biopsy system, centers can potentially expand their capacity for patients through the streamlined procedures and automated sampling. This all-in-one system no longer requires physicians and technologists to handle biopsy samples for analysis. Instead, tissue samples and calcifications are verified through the console’s automated core imaging setup.

“The integrity of samples cannot be underestimated. The specimen is part of the patient, so minimal handling is best,” said Dr. Borofsky. “With the Brevera system, we don’t touch the specimen. The whole system is contained, and it minimizes the potential for contamination.”



procedures because sampling more than two sites can take more than an hour and a half.

“Everything takes too long on other systems,” said Dr. Borofsky. “In my opinion, you can’t biopsy multiple sites without the Brevera system. It’s too much to ask a patient who is anxious and nervous to stay under compression for longer than an hour and a half, which means they have to come back, and it takes longer for a diagnosis.”

With Brevera system, stereotactic-guided biopsies can have a more efficient, patient-centered approach through the wealth of information conveyed by real-time imaging and secure samples.

“There’s a demand for biopsies,” said Dr. Borofsky. “There’s a need for capacity, in

order to be able to increase the number of procedures. Brevera system helps us increase capacity to offer more biopsies in a day. I consider it the next generation of biopsy devices.”



“The integrity of samples cannot be underestimated.”

Notably, Dr. Borofsky has been able to sample up to three calcification sites in a half hour using Brevera system. In comparison, with a traditional biopsy system, she has required patients to come back for multiple biopsy

1 2015 Kadence International survey of 200 healthcare professionals.

MISC-07807 Hologic, Inc. ©2021 All rights reserved. Hologic, Brevera, CorLumina, The Science of Sure, and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. Harriet Borofsky, MD, is a paid consultant for Hologic. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Views and opinions expressed herein by the medical professional are theirs alone and do not necessarily reflect those of Hologic. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are for sale in a particular country, please contact your local Hologic representative.

#### Important Safety Information

The Hologic® Brevera® breast biopsy system with CorLumina® imaging technology is intended to provide breast tissue samples for diagnostic sampling of breast abnormalities. The Brevera breast biopsy system excises targeted tissue and optionally delivers in-line radiographic images of the excised tissue. The Brevera breast biopsy system is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (for example, fibroadenoma, fibrocystic lesion), the Brevera breast biopsy system may also be used to partially remove such palpable lesions. The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of histological abnormality, for example, malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedure.

The Brevera breast biopsy system with CorLumina imaging technology is not intended for therapeutic applications. The Brevera breast biopsy system with CorLumina imaging technology is contraindicated for those patients who, based on the physician’s judgment, may be at increased risk or develop complications associated with core removal or biopsy. Patients receiving anticoagulant therapy or who may have bleeding disorders may be considered at increased risk of procedural complications. For detailed benefit and risk information, please consult the IFU.

**Brevera**<sup>®</sup>  
Breast Biopsy System